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To control symptoms and prevent increasing disability in
children with active polyarticular Juvenile Idiopathic
Arthritis (JIA), long-term, effective treatment that controls
all aspects of the disease is necessary. Individual ACR Pedi
response criteria were analyzed for the 128 patients who
entered the open-label extension (OLE) of the Phase III
study of adalimumab in the treatment of polyarticular JIA.
Measurements of disease activity were performed at each
visit, including active joint count (AJC), number of joints
with limitation of passive motion (LOM), parent's or
patient's assessment of patient's pain (PaP), disability
index of the Children's Health Assessment Questionnaire
(CHAQ DI), and physician's global assessment of disease
activity (PhDA). Observed data were examined for those
patients who had been treated with adalimumab through-
out the study and reached more than 1 year in the OLE
(Week 56; 75% of entering patients had data available).
Patients entering the study had active polyarticular JIA,
with clinically significant joint involvement, limitation of
motion, pain, and disability in performing daily living
activities. Long-term treatment with adalimumab pro-
vided marked improvements in disease activity (Table 1).
The established safety profile for adalimumab remained
consistent.
Long-term treatment with adalimumab substantially
improves multiple aspects of polyarticular JIA.
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Table 1: Improvements in JIA with adalimumab therapy
AJC* LOM** PaP† CHAQ DI‡ PhDA†
Baseline 17 14 49 1.05 57
Improvement at Week 56 of OLE 90% 70% 74% 83% 84%
*75 joints assessed, **69 joints assessed
†100-mm visual analog scale: greater scores = more active disease/more pain; ‡0 (best) to 3 (worst)